Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Renalytix plc (NASDAQ: RNLX) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023, in Snowbird, Utah.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023, in Snowbird, Utah. Unlike traditional conferences, there will be no formal company presentations; instead, management will engage in one-on-one meetings with investors, which can be scheduled through BTIG. Renalytix specializes in in-vitro diagnostics and is a leader in bioprognosis for kidney health. Their KidneyIntelX test helps assess risks of rapid kidney function decline among adults with Type 2 Diabetes and early Chronic Kidney Disease.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -5.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, Utah. Due to the format of this event there are no formal company presentations. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG (info@btig.com).
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
For further information, please contact:
| Renalytix plc | www.renalytix.com |
| James McCullough, CEO | Via Walbrook PR |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
| Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | |
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
| Gary Clarence / Ben Farrow | |
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com |
| Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 |
| CapComm Partners | |
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.